JP2018512585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512585A5 JP2018512585A5 JP2017548041A JP2017548041A JP2018512585A5 JP 2018512585 A5 JP2018512585 A5 JP 2018512585A5 JP 2017548041 A JP2017548041 A JP 2017548041A JP 2017548041 A JP2017548041 A JP 2017548041A JP 2018512585 A5 JP2018512585 A5 JP 2018512585A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- ecgf
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 102000013537 Thymidine Phosphorylase Human genes 0.000 claims 11
- 108700023160 Thymidine phosphorylases Proteins 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 239000013060 biological fluid Substances 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382109.5 | 2015-03-11 | ||
| EP15382109.5A EP3067698A1 (en) | 2015-03-11 | 2015-03-11 | Pd-ecgf as biomarker of cancer |
| PCT/EP2016/055143 WO2016142471A1 (en) | 2015-03-11 | 2016-03-10 | Pd-ecgf as biomarker of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144291A Division JP2020201278A (ja) | 2015-03-11 | 2020-08-28 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512585A JP2018512585A (ja) | 2018-05-17 |
| JP2018512585A5 true JP2018512585A5 (enExample) | 2019-04-04 |
Family
ID=52737037
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548041A Pending JP2018512585A (ja) | 2015-03-11 | 2016-03-10 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
| JP2020144291A Pending JP2020201278A (ja) | 2015-03-11 | 2020-08-28 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
| JP2022113650A Active JP7453284B2 (ja) | 2015-03-11 | 2022-07-15 | 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144291A Pending JP2020201278A (ja) | 2015-03-11 | 2020-08-28 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
| JP2022113650A Active JP7453284B2 (ja) | 2015-03-11 | 2022-07-15 | 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11802874B2 (enExample) |
| EP (2) | EP3067698A1 (enExample) |
| JP (3) | JP2018512585A (enExample) |
| KR (1) | KR102513020B1 (enExample) |
| CN (1) | CN107667292B (enExample) |
| AU (1) | AU2016231086B8 (enExample) |
| ES (1) | ES2896056T3 (enExample) |
| HK (1) | HK1250582A1 (enExample) |
| MX (1) | MX384046B (enExample) |
| PL (1) | PL3268744T3 (enExample) |
| WO (1) | WO2016142471A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021510835A (ja) * | 2018-01-15 | 2021-04-30 | フンダシオン インスティテュート デ インベスティガシオン サニタリア デ サンティアゴ デ コンポステーラ （フィディス） | Ｔａｓ１ｒ３タンパク質を発現する腫瘍に関する治療目的、診断目的及び／又は予後診断目的のマーカーとしてのｔａｓ１ｒ３タンパク質の使用 |
| US12624695B2 (en) | 2024-09-19 | 2026-05-12 | Mahle International Gmbh | Oil separator for compressor and compressor with oil separator |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3268147B2 (ja) | 1994-12-28 | 2002-03-25 | 大鵬薬品工業株式会社 | モノクローナル抗体 |
| US20050175980A1 (en) | 2002-04-09 | 2005-08-11 | Government Of The United States Of America, Repres By The Secretary, Dept. Of Health And Human Serv. | Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule |
| AU2003298689A1 (en) | 2002-11-21 | 2004-06-18 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| CN1882698B (zh) | 2003-08-20 | 2011-05-25 | 肿瘤疗法科学股份有限公司 | 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶 |
| ES2279266T3 (es) * | 2003-08-28 | 2007-08-16 | F. Hoffmann-La Roche Ag | Correlacion del cociente de los niveles de expresion del mrna de la timidina fosforilasa y la dihidropirimidina dehidrogenasa en el cancer colorrectal con supervivencia libre de enfermedad en pacientes tratados con 5-fu. |
| WO2007115376A1 (en) | 2006-04-11 | 2007-10-18 | The University Of Western Australia | Anti-angiogenic agents and methods of their use |
| US8642349B1 (en) * | 2006-08-11 | 2014-02-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial neural network proteomic tumor classification |
| US20130178383A1 (en) * | 2008-11-12 | 2013-07-11 | David Spetzler | Vesicle isolation methods |
| CA2751888C (en) * | 2009-02-11 | 2022-06-14 | Caris Mpi, Inc. | Molecular profiling of tumors |
| US20120282631A1 (en) * | 2009-03-20 | 2012-11-08 | The Hong Kong Polytechnic University | Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers |
| US20100317029A1 (en) * | 2009-06-15 | 2010-12-16 | Lih-Chyang Chen | Nasopharyngeal cancer malingancy biomarker and method thereof |
| US8110675B2 (en) | 2009-06-15 | 2012-02-07 | Chang Gung University | TP expression-inhibiting compound and siRNA sequence thereof |
| CN101993919A (zh) * | 2009-08-10 | 2011-03-30 | 芮屈生物技术（上海）有限公司 | 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用 |
| US9128101B2 (en) * | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| WO2012129448A1 (en) | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
| AU2013207778B2 (en) * | 2012-01-13 | 2017-10-12 | Genentech, Inc. | Biological markers for identifying patients for treatment with VEGF antagonists |
-
2015
- 2015-03-11 EP EP15382109.5A patent/EP3067698A1/en not_active Withdrawn
-
2016
- 2016-03-10 WO PCT/EP2016/055143 patent/WO2016142471A1/en not_active Ceased
- 2016-03-10 AU AU2016231086A patent/AU2016231086B8/en active Active
- 2016-03-10 JP JP2017548041A patent/JP2018512585A/ja active Pending
- 2016-03-10 CN CN201680013857.4A patent/CN107667292B/zh active Active
- 2016-03-10 ES ES16709410T patent/ES2896056T3/es active Active
- 2016-03-10 US US15/556,568 patent/US11802874B2/en active Active
- 2016-03-10 MX MX2017011467A patent/MX384046B/es unknown
- 2016-03-10 EP EP16709410.1A patent/EP3268744B1/en active Active
- 2016-03-10 KR KR1020177025613A patent/KR102513020B1/ko active Active
- 2016-03-10 HK HK18109182.9A patent/HK1250582A1/zh unknown
- 2016-03-10 PL PL16709410T patent/PL3268744T3/pl unknown
-
2020
- 2020-08-28 JP JP2020144291A patent/JP2020201278A/ja active Pending
-
2022
- 2022-07-15 JP JP2022113650A patent/JP7453284B2/ja active Active
-
2023
- 2023-10-27 US US18/384,508 patent/US12298307B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoseok et al. | Lung cancer biomarkers | |
| Jiang et al. | Detection and clinical significance of circulating tumor cells in colorectal cancer | |
| e Silva et al. | Assessment of kidney function in patients with cancer | |
| JP2014533960A5 (enExample) | ||
| Gong et al. | Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma | |
| JP2013517476A5 (enExample) | ||
| Katono et al. | Clinicopathological significance of S100A10 expression in lung adenocarcinomas | |
| Noguera et al. | Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube | |
| JP2017526916A5 (enExample) | ||
| Ding et al. | Gab2 is a novel prognostic factor for colorectal cancer patients | |
| Shimura et al. | C-reactive protein is a potential prognostic factor for metastatic gastric cancer | |
| Pan et al. | The Glasgow Prognostic Score is an independent prognostic predictor of hepatocellular carcinoma following radical resection | |
| Kastritis et al. | The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy | |
| JP2017529852A5 (enExample) | ||
| Uratani et al. | Preoperative lower body mass index correlates with poorer prognosis in patients undergoing curative laparoscopic surgery for colorectal cancer | |
| Horn et al. | The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer | |
| WO2016161153A3 (en) | Prognostic and diagnostic methods for colorectal cancer | |
| JP2019516104A5 (enExample) | ||
| Asegaonkar et al. | Serum high sensitivity C-reactive protein in breast cancer patients | |
| JP2012515893A5 (enExample) | ||
| JP2016502083A5 (enExample) | ||
| Laguna | Re: Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904 | |
| Lamarca et al. | Tumoural expression of connective tissue growth factor (CTGF) impacts on survival in patients diagnosed with hepatocellular carcinoma (HCC) | |
| CN104111332A (zh) | 基于蛋白标志物pak4辅助诊断非小细胞肺癌患者的试剂盒 | |
| CN103323589A (zh) | 基于血清中il-22表达量预测结直肠癌患者化疗抵抗情况的方法 |